PDF herunterladen
Open Access
CC BY 4.0 · World J Nucl Med 2025; 24(03): 221-230
DOI: 10.1055/s-0045-1812307
Review Article

Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects

Autor*innen

  • Ismaheel O. Lawal

    1   Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States
    2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa

  • Honest Ndlovu 

    2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
    3   Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa

  • Joseph Kabunda

    2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
    3   Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa

  • Kgomotso M. Mokoala

    2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
    3   Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa

  • Mike M. Sathekge 

    2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
    3   Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

There is a global rise in the number of new cancer diagnoses and cancer deaths. Rising new cancer diagnoses and deaths from low- and middle-income countries (LMICs) are the biggest contributors to this global trend. Efforts geared toward prevention, timely diagnosis, effective treatment, and efficient cancer survivorship programs are needed to address the rising scourge of cancer in LMICs. Radiotheranostics entails using radiopharmaceuticals for diagnostic imaging and therapy of diseases. Functional imaging, as in radiotheranostics, is more sensitive for disease detection and treatment response assessment than conventional cross-sectional imaging. Therefore, radiotheranostics has the potential to address some of the strategies to curtail the rising scourge of cancer and its mortality in LMICs, including timely diagnosis, effective management, and disease surveillance. Many key issues hinder the widespread availability, access, and utilization of nuclear medicine (NM) and radiotheranostics services in LMICs. These issues include scarcity of trained (NM) professionals, lack of training for (NM) personnel, poor infrastructure, inadequate awareness of NM and radiotheranostics, poor funding, and poorly conceived regulations that stifle NM practice. Despite these hindrances, many success stories have emerged from LMICs regarding clinical application of radiotheranostics. For example, many practice-defining studies have been published by groups from LMICs regarding prostate-specific membrane antigen-targeted imaging and therapy of prostate cancer. Specifically, notable contributions have been made to the literature by groups from South Africa, India, and Türkiye on the safety and efficacy of 225Ac-PSMA-617 for therapy of advanced prostate cancer. Through the intervention of many international organizations, governments, and private sectors, there has been a steady improvement in the awareness, availability, access, and utilization of NM and radiotheranostics services in LMICs.

Keywords

radiotheranostics - nuclear medicine - low- and middle-income countries - prostate cancer - 225Ac-PSMA - 177Lu-PSMA


Publikationsverlauf

Artikel online veröffentlicht:
14. Oktober 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India